Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EBITDA (2020 - 2025)

Historic EBITDA for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$15.8 million.

  • Foghorn Therapeutics' EBITDA rose 1434.54% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.5 million, marking a year-over-year increase of 1855.91%. This contributed to the annual value of -$85.7 million for FY2024, which is 1008.44% up from last year.
  • As of Q3 2025, Foghorn Therapeutics' EBITDA stood at -$15.8 million, which was up 1434.54% from -$18.0 million recorded in Q2 2025.
  • Foghorn Therapeutics' EBITDA's 5-year high stood at -$13.5 million during Q3 2023, with a 5-year trough of -$29.4 million in Q1 2023.
  • Its 5-year average for EBITDA is -$23.6 million, with a median of -$23.1 million in 2021.
  • As far as peak fluctuations go, Foghorn Therapeutics' EBITDA crashed by 6465.74% in 2021, and later soared by 5073.97% in 2023.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' EBITDA stood at -$29.1 million in 2021, then rose by 3.88% to -$28.0 million in 2022, then rose by 17.74% to -$23.0 million in 2023, then grew by 14.37% to -$19.7 million in 2024, then increased by 20.01% to -$15.8 million in 2025.
  • Its last three reported values are -$15.8 million in Q3 2025, -$18.0 million for Q2 2025, and -$19.0 million during Q1 2025.